# A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Source: https://onco.cc/trials/nct04931654/  
OnCo record `nct04931654` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD7789 in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer is a phase 1/2 interventional study registered as NCT04931654 by AstraZeneca, with 136 participants enrolled, started 2021-09-28 and due to reach its primary completion in 2024-12-04. Interventions recorded: AZD7789.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04931654
- Phase: 1/2
- Setting: A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
- Sponsor: AstraZeneca
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT04931654: https://clinicaltrials.gov/study/NCT04931654

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [AZD7789](https://onco.cc/drugs/azd7789/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04931654.json